Venus Remedies Limited is an entirely integrated Company, recognized around the globe for its research and development initiatives and breakthroughs. It is backed by world class manufacturing facilities attributed with national and international certifications, state-of-the-art research centre named as Venus Medicine Research Centre, rich Intellectual Property Wealth, a strong marketing network worldwide together with dedicated and highly efficient professionals. The company is a pioneer in manufacturing world class products in critical care segments such as Anti cancer, Anti infective, Neurology, Skin & Wound care, and Pain management.
Today, Venus Remedies share price had surged over 14 percent from its previous close to trade at the intraday high of Rs. 105.
The company had unveiled its Q2 results on 18th November. The total sales of the company stood at Rs. 107.12 crores in the September quarter as compared to Rs. 103 crores in June quarter in the same financial year and Rs. 105.94 crores in the September quarter of the last financial year. The net profit was lower for the quarter due to the higher expenditure. The expenditure in Q2FY17 stood at Rs. 97.81 crores while it was Rs. 95.13 crores in the previous quarter and Rs. 95.72 crores in the year ago quarter. The company had posted the PAT of Rs. 1.14 cores in Q2FY17 as compared to Rs. 1.18 crores in Q1FY17 and Rs. 1.61 crores in Q2FY16. The company has also posted the lower EPS of Re. 1 in the September quarter as compared to Rs. 1.03 in the June quarter of the same financial year and Rs. 140 in the September quarter of the last financial year.
At 11:55 AM Venus Remedies was trading at Rs. 101.60, up by 10.37%.
Venus Remedies is the top 500 performing stock for the quarter as identified by Dynamic Levels. For the support and resistance levels of Venus Remedies Visit Venus Remedies share price forecast page of Dynamic Levels website.
No comments:
Post a Comment